Physician profile
Michael Whiting Ryan
NPI 1134278799
$523.57
in general payments reported to CMS, 2019-2025
13 companies · $61.02 in 2025
The $61.02 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.79 · 2022: $33.01 · 2023: $139 · 2024: $252 · 2025: $61.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $145.37 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $124.99 | 2023 | Farxiga |
| Abbvie INC. | $61.69 | 2022-2024 | |
| Pentax of America, INC. | $40.33 | 2022-2024 | Pentax Medical, Inspira, C2 Cryoballoon Focal Controller |
| Madrigal Pharmaceuticals | $25.13 | 2025 | Rezdiffra |
| Pfizer INC. | $22.92 | 2024 | |
| Novo Nordisk INC | $18.40 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $17.49 | 2025 | Voquezna |
| Qol Medical, LLC | $16.19 | 2019 | |
| Lilly USA, LLC | $14.51 | 2024 | Omvoh |
| Amgen INC. | $13.95 | 2023 | Amjevita |
| Janssen Biotech, INC. | $11.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.